Health authority approves Covid treatment pills
The South African Health Products Regulatory Authority (Sahpra) has authorised the use of molnupiravir in the country for the treatment of Covid-19 positive adults who do not require oxygen but who are at risk of progression to severe Covid-19.
The molnupiravir 200 mg capsules, or LAGEVRIO, were authorised with conditions.
Sahpra CEO Dr Boitumelo Semete-Makokotlela pointed out that this authorisation is for a limited quantity of “Lagevrio” and is initially limited to six months.
“The authorisation of molnupiravir for compassionate use offers further therapy in the fight against Covid-19. Sahpra will continue to play its part in ensuring the quality, safety and efficacy of all health products, including innovative treatments so that the public is protected at all times,” she said.
In a clinical trial, molnupiravir was shown to reduce the risk of hospitalisation or death compared with placebo, but only when treatment was initiated within five days of the first symptoms of Covid-19.
Molnupiravir is only indicated for use in patients aged 18 years and older and will require a prescription.
The treatment is not recommended for pregnant women and Semete-Makokotlela further stressed that women of childbearing potential should use contraception for the duration of treatment and for 4 days after the last dose.
The Regulatory Authority is also reviewing applications for the use of generic products containing molnupiravir.
Sahpra is also considering Pfizer’s application for the co-packaged presentation of nirmatrelvir and ritonavir “paxlovid”.
Comments
Research Reports
Projects
Latest News
Showroom
Leading condition monitoring specialists, WearCheck, help boost machinery lifespan and reduce catastrophic component failure through the scientific...
VISIT SHOWROOM
Avlock International is a leading manufacturer and distributor of Specialized Fastening Systems.
VISIT SHOWROOM
Press Office
Announcements
What's On
Subscribe to improve your user experience...
Option 1 (equivalent of R125 a month):
Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format
Option 2 (equivalent of R375 a month):
All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors
including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.
Already a subscriber?
Forgotten your password?
Receive weekly copy of Creamer Media's Engineering News & Mining Weekly magazine (print copy for those in South Africa and e-magazine for those outside of South Africa)
➕
Recieve daily email newsletters
➕
Access to full search results
➕
Access archive of magazine back copies
➕
Access to Projects in Progress
➕
Access to ONE Research Report of your choice in PDF format
RESEARCH CHANNEL AFRICA
R4500 (equivalent of R375 a month)
SUBSCRIBEAll benefits from Option 1
➕
Access to Creamer Media's Research Channel Africa for ALL Research Reports on various industrial and mining sectors, in PDF format, including on:
Electricity
➕
Water
➕
Energy Transition
➕
Hydrogen
➕
Roads, Rail and Ports
➕
Coal
➕
Gold
➕
Platinum
➕
Battery Metals
➕
etc.
Receive all benefits from Option 1 or Option 2 delivered to numerous people at your company
➕
Multiple User names and Passwords for simultaneous log-ins
➕
Intranet integration access to all in your organisation
